Projects per year
Personal profile
Personal profile
Dr. Zeenat Safdar is a Professor of Medicine, Houston Methodist Academic Institute, and Director of Clinical Research and Pulmonary Hypertension Program, Houston Methodist Hospital Lung Center in Houston, Texas. She is also an Adjunct Associate Professor of Medicine at Baylor College of Medicine.
Dr. Safdar serves as a Chair of Young Council at Pulmonary Vascular Research Institute, Pulmonology Chair at the Pulmonary Hypertension Association Online University, and National Chair at PHA on the Road program. She serves as Registries and Databases Workforce leader at PH council of International Society of Heart Lung Transplantation (ISHLT).
Dr. Safdar is a Fellow of the American College of Physicians, American College of Chest Physicians (CHEST), and Pulmonary Vascular Research Institute. She is a member of the PH Council of International Society of Heart Lung Transplant, American Thoracic Society and Texas Medical Association.
She has been invited to serve as the session facilitator, presenter, and abstract reviewer and selector at the International Conference of the ATS, CHEST and ISHLT. Dr. Safdar has served as an invited reviewer for the American Journal of Respiratory and Critical Care Medicine, Respiratory Medicine and Therapeutic Advances in Respiratory Disease and serves as a member of the editorial board of several journals.
Research interests
Dr. Safdar’s principal area of interest is Pulmonary Arterial Hypertension (PAH), specifically translational research, clinical research and clinical trials. Her recent research has focused on the contribution of renin-angiotensin-aldosterone system to the pathophysiology of PAH. She is the principal and co-investigator of several ongoing clinical trials including
- REATA - a phase 2 dose-ranging study of efficacy and safety of Bardoxolone Methyl in PAH
- LIBERTY - a phase 2 study of Ubenimex in patient with PAH
- TRANSIT-1 - a study to Assess the Tolerability and the Safety of the Transition From Inhaled Treprostinil to Oral Selexipag in PAH
- Chronic ThromboEmbolic Pulmonary Hypertension registry
- TRITON - The Efficacy and Safety of Initial Triple Versus Initial Dual Oral Combination Therapy in Patients With Newly Diagnosed PAH
- RIN-PH - Safety and Efficacy of Inhaled Treprostinil in Adult PH With ILD Including CPFE
The Houston Methodist Hospital Pulmonary Hypertension program also provides expert care for patients with idiopathic pulmonary fibrosis (IPF). As a Director of the IPF program, she serves as a lead investigator of several ongoing IPF clinical trials including
- RIFF study - a phase 2 randomized placebo-controlled clinical study to assess the safety and efficacy of Lebrikizumab in IPF
- RAINIER study - a phase 2 multicenter study to assess the efficacy and safety of Simtuzamab in IPF
She was the site investigator of several complete IPF clinical trials such as
- ARTEMIS-IPF - ambrisentan for IPF
- ARTEMIS-PH - ambrisentan in PH associated with IPF
- MUSIC - macitentan for IPF
Dr. Safdar is the recipient of a K23 grant from the National Institute of Health (NIH) and several other grants from non-profit organizations. Her research has been published in prominent, high impact journals.
External positions
Professor of Clinical Medicine, Weill Cornell Medical College
Jan 1 2016 → …
Research Area Keywords
- Clinical Translation & Trials
- Clinical Care
Free-text keywords
- Pulmonary Arterial Hypertension (PAH)
- Idiopathic Pulmonary Fibrosis (IPF)
- Pulmonary disease
Fingerprint
- 1 Similar Profiles
Collaborations and top research areas from the last five years
-
-
Gossamer_GB002-2102_Phase 2 OLE_Pulmonary Arterial Hypertension An Open-label Extension Study Evaluating the Long-term Safety and Efficacy of Oral Inhalation of GB002 for the Treatment of WHO Group 1 Pulmonary Arterial Hypertension (PAH)
Sahay, S., Guha, A. & Safdar, Z.
9/15/21 → …
Project: Clinical Trial
-
Effect of Antifibrotic Therapy on Survival in Patients With Idiopathic Pulmonary Fibrosis
IPF-PRO Registry investigators, Apr 2023, In: Clinical Therapeutics. 45, 4, p. 306-315 10 p.Research output: Contribution to journal › Article › peer-review
Open Access1 Scopus citations -
Integrative multi-omics analysis reveals novel idiopathic pulmonary fibrosis endotypes associated with disease progression
Ruan, P., Todd, J. L., Zhao, H., Liu, Y., Vinisko, R., Soellner, J. F., Schmid, R., Kaner, R. J., Luckhardt, T. R., Neely, M. L., Noth, I., Porteous, M., Raj, R., Safdar, Z., Strek, M. E., Hesslinger, C., Palmer, S. M., Leonard, T. B. & Salisbury, M. L., May 31 2023, In: Respiratory Research. 24, 1, p. 141 141.Research output: Contribution to journal › Article › peer-review
Open Access2 Scopus citations -
Associations between resources and practices of ILD centers and outcomes in patients with idiopathic pulmonary fibrosis: data from the IPF-PRO Registry
The IPF-PRO Registry Investigators, Jan 7 2022, In: Respiratory Research. 23, 1, p. 3 3.Research output: Contribution to journal › Article › peer-review
Open Access -
Delphi consensus recommendation for optimization of pulmonary hypertension therapy focusing on switching from a phosphodiesterase 5 inhibitor to riociguat
Rahaghi, F. F., Balasubramanian, V. P., Bourge, R. C., Burger, C. D., Chakinala, M. M., Eggert, M. S., Elwing, J. M., Feldman, J., King, C., Klinger, J. R., Mathai, S. C., McConnell, J. W., Palevsky, H. I., Restrepo-Jaramillo, R., Safdar, Z., Sager, J. S., Sood, N., Sulica, R., White, R. J. & Hill, N. S., Apr 2022, In: Pulmonary Circulation. 12, 2, e12055.Research output: Contribution to journal › Article › peer-review
Open Access3 Scopus citations -
Disparities in Lung Transplant among Patients with Idiopathic Pulmonary Fibrosis An Analysis of the IPF-PRO Registry
The IPF-PRO Registry Investigators, Jun 2022, In: Annals of the American Thoracic Society. 19, 6, p. 981-990 10 p.Research output: Contribution to journal › Article › peer-review
7 Scopus citations